Lexeo Therapeutics announced updates to key components of an Accelerated Approval pathway for LX2006 in Friedreich ataxia (FA) cardiomyopathy and new interim clinical data from their ongoing Phase I/II studies. Read their letter to the FA community at Pharma News - National Ataxia Foundation.
1 Like